|Bid||2.9300 x 3100|
|Ask||2.9500 x 28000|
|Day's Range||2.9200 - 2.9600|
|52 Week Range||1.4500 - 3.2800|
|Beta (3Y Monthly)||1.62|
|PE Ratio (TTM)||10.46|
|Earnings Date||Nov 11, 2019 - Nov 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
WILMINGTON, Del., Sept. 19, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: SemGroup Corporation (NYSE: SEMG) regarding possible breaches of fiduciary.
NEW YORK , Sept. 18, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
NEW YORK , Sept. 17, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Fibrocell Science, Inc. (NASDAQ: FCSC) on behalf of Fibrocell shareholders ...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Fibrocell Science, Inc.
WILMINGTON, DE / ACCESSWIRE / September 16, 2019 / Rigrodsky & Long, P.A.: Do you own shares of Fibrocell Science, Inc. (NASDAQ GS: FCSC )? Did you purchase any of your shares prior to September 12, 2019? ...
NEW YORK, Sept. 16, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Fibrocell Science, Inc..
The proposed deal involves two companies focused on development new treatments for patients with rare, debilitating and serious dermatologic conditions.
Castle Creek Pharmaceutical Holdings announced it will acquire Fibrocell Science, Inc. (NASDAQ: FCSC ), a cell and gene therapy company in a $3 per share cash. Castle Creek Pharmaceuticals is a privately ...
PARSIPPANY, N.J., Sept. 12, 2019 /PRNewswire/ -- Castle Creek Pharmaceutical Holdings, Inc. ("CCP Holdings") today announced it has reached an agreement to acquire Fibrocell Science, Inc. (FCSC), a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases. With the resources of CCP Holdings' subsidiary, Castle Creek Pharmaceuticals, LLC ("Castle Creek"), a privately held biopharmaceutical company developing innovative therapies for patients with rare, serious or debilitating dermatologic conditions, Fibrocell's gene therapy platform can be advanced into additional areas of high, unmet need with the potential to develop multiple, promising new therapies.
Fibrocell Science, Inc. (FCSC), a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced it has reached an agreement to be acquired by Castle Creek Pharmaceutical Holdings, Inc. (“Castle Creek Pharmaceutical Holdings”), the parent company of Castle Creek Pharmaceuticals, LLC “Castle Creek Pharmaceuticals”). Castle Creek Pharmaceutical Holdings will acquire Fibrocell for a total consideration of approximately $63.3 million, including repayment of debt and other financial instruments, in cash. Fibrocell common stockholders will receive all-cash consideration of $3.00 per share.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 14) GENMAB A/S/S ADR (NASDAQ: GMAB ) (announced first-half ...
- Company to Host Conference Call and Webcast on Thursday, August 15 at 8:30 a.m. EDT - EXTON, Pa., Aug. 14, 2019 -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy.
If you're interested in Fibrocell Science, Inc. (NASDAQ:FCSC), then you might want to consider its beta (a measure of...
Savara's (SVRA) lead pipeline candidate, Molgradex, fails to meet primary endpoint in a phase III study evaluating it in a rare autoimmune lung disorder.
Fibrocell's (FCSC) gene therapy for a genetic skin disorder gets Regenerative Medicine Advanced Therapy designation, which expedites development process.
EXTON, Pa., May 30, 2019 -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective.
EXTON, Pa., May 29, 2019 -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective.
The Zacks Analyst Blog Highlights: Limbach, Health Insurance, Fibrocell, Camden and First Business
“We achieved important milestones during the first several months of 2019 for our gene therapy clinical programs focused on devastating, rare genetic conditions of the skin and connective tissue with high unmet medical needs,” said John Maslowski, President and Chief Executive Officer of Fibrocell. “Most recently, we announced our collaboration with Castle Creek Pharmaceuticals to develop and commercialize FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). “Furthermore, we completed a Type B end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss the design of a Phase 3 clinical trial for FCX-007. Based on the FDA’s feedback from this meeting, we are incorporating their comments into our Investigational New Drug (IND) application for FCX-007, and expect to initiate the Phase 3 trial in the second quarter of 2019.